{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"}]}],"title":"Anemia, Increased to Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}],"title":"Anemia, Increased to Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Anemia, Increased to Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"title":"Neutrophil count decreased, Increased to Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Neutrophil count decreased, Increased to Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Neutrophil count decreased, Increased to Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"title":"White blood cell decreased, Increased to Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"White blood cell decreased, Increased to Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"White blood cell decreased, Increased to Grade 4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"description":"Blood samples were collected for the analysis of following hematology parameters: anemia, neutrophil count decreased and white blood cell decreased. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G2, G3, and G4 are presented. The laboratory parameters were graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.","groups":[{"description":"Adult participants (≥ 18 years) were administered Tovorafenib 600 mg orally (PO) once weekly (QW).","id":"OG000","title":"Melanoma Cohort"},{"description":"Adult participants (≥ 18 years) were administered Tovorafenib 600 mg PO QW.","id":"OG001","title":"Tissue Agnostic Cohort"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Analysis Set comprises of all patients enrolled in the study who receive at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"Baseline and up to 23 months","title":"Number of Participants With Worst Case Hematology Results by Maximum Grade Increase Post-baseline Relative to Baseline","type":"SECONDARY","unitOfMeasure":"Participants"}